Adlai Nortye Ltd. American Depositary Shares (ANL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Adlai Nortye Ltd. American Depositary Shares stock (ANL) is currently trading at $6.99. Adlai Nortye Ltd. American Depositary Shares PS ratio (Price-to-Sales) is 15.50. Analyst consensus price target for ANL is $28.33. WallStSmart rates ANL as Sell.
- ANL PE ratio analysis and historical PE chart
- ANL PS ratio (Price-to-Sales) history and trend
- ANL intrinsic value — DCF, Graham Number, EPV models
- ANL stock price prediction 2025 2026 2027 2028 2029 2030
- ANL fair value vs current price
- ANL insider transactions and insider buying
- Is ANL undervalued or overvalued?
- Adlai Nortye Ltd. American Depositary Shares financial analysis — revenue, earnings, cash flow
- ANL Piotroski F-Score and Altman Z-Score
- ANL analyst price target and Smart Rating
Adlai Nortye Ltd. American Depositary Shares
📊 No data available
Try selecting a different time range
Smart Analysis
Adlai Nortye Ltd. American Depositary Shares (ANL) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Adlai Nortye Ltd. American Depositary Shares (ANL) Key Strengths (1)
Revenue surging 118.00% year-over-year
Supporting Valuation Data
Adlai Nortye Ltd. American Depositary Shares (ANL) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 15.5x annual revenue
Very expensive at 55.1x book value
Very low institutional interest at 6.19%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Adlai Nortye Ltd. American Depositary Shares (ANL) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 118.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (15.50), Price/Book (55.10) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -139.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -139.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 118.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ANL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ANL's Price-to-Sales ratio of 15.50x trades 30% below its historical average of 22.06x (54th percentile). The current valuation is 82% below its historical high of 85.98x set in Apr 2024, and 179% above its historical low of 5.55x in Oct 2023. Over the past 12 months, the PS ratio has expanded from ~12.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Adlai Nortye Ltd. American Depositary Shares (ANL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Adlai Nortye Ltd. American Depositary Shares is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 2M with 118% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 118% YoY, reaching 2M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 2316% of revenue (45M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -52M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Debt-to-equity ratio of 5.63 is elevated. High leverage amplifies both gains and losses and increases financial risk.
What to Watch Next
Growth sustainability: can Adlai Nortye Ltd. American Depositary Shares maintain 118%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Adlai Nortye Ltd. American Depositary Shares.
Bottom Line
Adlai Nortye Ltd. American Depositary Shares is a high-conviction growth story with revenue accelerating at 118% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Adlai Nortye Ltd. American Depositary Shares(ANL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.